MYCBP Activators
MYCBP, a MYC binding protein, is subject to activation through a variety of indirect mechanisms facilitated by specific chemical activators that influence signaling pathways or biological processes in which MYCBP is involved. Phorbol 12-myristate 13-acetate (PMA), for instance, bolsters MYCBP activity by activating protein kinase C (PKC), which can enhance the phosphorylation of MYC and stabilize the MYC-MYCBP interaction. Similarly, Forskolin raises intracellular cAMP levels, activating protein kinase A (PKA) that may phosphorylate proteins within the MYC network, potentially affecting MYCBP's functional role. 5-Azacytidine influences chromatin structure and DNA methylation, respectively, leading to altered gene expression patterns that could upregulate MYC or its associated proteins, indirectly augmenting MYCBP's activity. Proteasome inhibition by MG-132 stabilizes ubiquitinated proteins, including MYCBP, thus enhancing its function by preventing degradation.
Additional compounds like nicotinamide modulate the acetylation of histones and proteins, which can impact MYC transcriptional activity and the function of associated proteins, thereby influencing MYCBP. The PARP inhibitor Olaparib and the pan-caspase inhibitor Z-VAD-FMK may affect MYC pathway and apoptosis, respectively, with potential upshots on MYCBP activity due to altered protein interactions and stability. Okadaic acid's inhibition of phosphatases leads to heightened phosphorylation states that could indirectly enhance MYCBP's role. Furthermore, CDK4/6 inhibitor Palbociclib and MNK1 inhibitor CGP 57380 affect cell cycle progression and MYC translation, respectively, which could lead to an amplified activity of MYCBP due to shifts in MYC protein levels. These chemical activators, despite their varied targets and mechanisms, converge on the modulation of pathways and processes that are poised to elevate the functional activity of MYCBP without directly increasing its expression or binding capabilities.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diester of phorbol and is known to activate protein kinase C (PKC), which can then influence various signaling pathways. Given that MYCBP is a MYC binding protein, and MYC is a substrate of PKC in certain contexts, PMA may enhance the activity of MYCBP by promoting the phosphorylation of MYC, thereby potentially stabilizing the MYC-MYCBP interaction. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is an activator of adenylate cyclase, leading to an increase in cAMP levels and activation of PKA. PKA can phosphorylate a wide range of targets and may enhance MYCBP activity by modifying the phosphorylation state of proteins that interact with MYCBP or MYC, potentially affecting MYCBP's function. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor. By reducing DNA methylation, it can increase the expression of genes that may interact with MYCBP, potentially enhancing its activity by increasing the concentration of its binding partners. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. This could stabilize MYCBP and its associated proteins, including MYC, indirectly leading to an enhancement of MYCBP's function due to increased protein stability. | ||||||
Nicotinamide | 98-92-0 | sc-208096 sc-208096A sc-208096B sc-208096C | 100 g 250 g 1 kg 5 kg | $44.00 $66.00 $204.00 $831.00 | 6 | |
Nicotinamide is a form of vitamin B3 and acts as an inhibitor of sirtuins, which are NAD+-dependent deacetylases. By inhibiting sirtuins, nicotinamide could impact the acetylation state of MYC or other proteins in the MYC network, potentially enhancing MYCBP activity. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib is a PARP inhibitor. By preventing the PARP-mediated ADP-ribosylation, it could affect the MYC pathway and thereby possibly enhance MYCBP activity, as PARP inhibitors are known to interact with DNA repair pathways and thus may indirectly influence transcription factors like MYC. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor that can prevent apoptosis. By inhibiting caspases, it might stabilize MYC and its interacting proteins, including MYCBP, thereby potentially enhancing MYCBP's function. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A. This inhibition can lead to increased phosphorylation of various proteins, which could enhance the activity of MYCBP through indirect effects on the MYC pathway. | ||||||
CGP 57380 | 522629-08-9 | sc-202993 | 5 mg | $172.00 | 6 | |
CGP 57380 is an inhibitor of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1). MNK1 can influence the translation of MYC, and its inhibition by CGP 57380 could lead to changes in MYC protein levels, potentially enhancing the activity of MYCBP. | ||||||